MRNA financials
Moderna, Inc. · end-of-day data as of Oct 16, 2026
Moderna, Inc.
$218.01+303.2%
Hold · 24 analystsPT $163.56 -25.0%
MRNA reported revenue of $145M for the quarter ended Jun 30, 2026 (Q2 FY2026), up 2.1% from a year earlier. It posted diluted EPS of -$1.96, free cash flow of -$563M and a net margin of -539.3%.
Valuation
- P/E—
- P/E vs own—
- P/E vs sector—
- FCF yield-1.4%
- Market cap$87.04B
Quarterly results
Q2 FY2026: Revenue +2.1% year over year, free cash flow -388.3% of revenue, operating margin -562.1%.
RevenueFree cash flow
| Q2 FY2026 | Jun 30, 2026 | $145M | -1.96 | -$563M | 35.9% | -562.1% | -539.3% |
| Q1 FY2026 | Mar 31, 2026 | $389M | -3.40 | -$692M | -145.5% | -356.8% | -345.2% |
| Q4 FY2025 | Dec 31, 2025 | $678M | -2.11 | $912M | 33.3% | -126.4% | -121.8% |
| Q3 FY2025 | Sep 30, 2025 | $1.02B | -0.51 | -$880M | 0.8% | -25.6% | -19.7% |
| Q2 FY2025 | Jun 30, 2025 | $142M | -2.13 | -$922M | 16.2% | -638.7% | -581.0% |
| Q1 FY2025 | Mar 31, 2025 | $107M | -2.52 | -$1.16B | 15.9% | -981.3% | -907.5% |
| Q4 FY2024 | Dec 31, 2024 | $956M | -2.91 | $303M | 22.7% | -130.3% | -117.2% |
| Q3 FY2024 | Sep 30, 2024 | $1.85B | 0.03 | -$1.72B | 72.3% | -3.8% | 0.7% |
| Q2 FY2024 | Jun 30, 2024 | $221M | -3.33 | -$1.46B | 48.0% | -616.7% | -578.7% |
| Q1 FY2024 | Mar 31, 2024 | $167M | -3.08 | -$1.19B | 42.5% | -758.1% | -703.6% |
| Q4 FY2023 | Dec 31, 2023 | $2.81B | 0.55 | $402M | 67.0% | 0.2% | 7.7% |
| Q3 FY2023 | Sep 30, 2023 | $1.83B | -9.53 | -$1.74B | -22.4% | -109.9% | -198.3% |